TORONTO – Life-sciences company MDS Inc. forms a committee of independent directors to support the company’s continuing process of assessing ways to improve shareholder value. MDS emphasizes that there can be no assurance that this process will result in any specific strategic or financial transaction, especially considering the current uncertain economic conditions. No timetable has been set for its completion. Last July, MDS filed a $1.4 billion court claim against Atomic Energy of Canada Limited (AECL) and the Government of Canada for cancellation of an order for two MAPLE nuclear reactors to produce a long-term supply of nuclear isotopes to MDS, required by patients worldwide for serious medical needs. Click here for more information.